SCHEDULE: Vanguard Discloses 5.93% Stake in 10X Genomics

Vanguard Portfolio Management has reported a beneficial ownership of 5.93% in 10X Genomics Inc. common stock as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, has disclosed a beneficial ownership of 6,981,683 shares of 10X Genomics Inc. common stock.
• This holding represents 5.93% of the total class of securities.
• The filing indicates that Vanguard Portfolio Management has sole voting power over 68,747 shares and sole dispositive power over 6,981,683 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake by a major institutional investor, which is generally positive, but it does not contain operational or financial performance data for 10X Genomics itself.

Positives

• Vanguard's significant stake suggests confidence in 10X Genomics' long-term prospects.
• The filing confirms that the shares are held in the ordinary course of business, indicating a standard investment approach rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk in this filing, any significant shift in Vanguard's holdings could impact 10X Genomics' stock price due to the large volume involved.

Future Outlook

This filing does not contain forward-looking statements or guidance from 10X Genomics. It solely reports Vanguard's ownership stake.

Industry Context

StockSavvy.ai notes that large institutional investors like Vanguard filing Schedule 13G forms often signal significant, albeit passive, interest in a company's stock. This filing indicates Vanguard's substantial investment in the life sciences and biotechnology sector, where 10X Genomics operates.

Stakeholder Impact

• Shareholders: The filing confirms a substantial institutional investor's stake, which can be viewed positively for stock stability and potential future institutional interest.
• Management: The filing does not directly impact management but reinforces the need for continued performance to satisfy large investors like Vanguard.

Next Steps

• Vanguard will continue to hold its shares in 10X Genomics in the ordinary course of business.
• Future filings will be made if Vanguard's ownership stake changes significantly.

Key Dates

Keywords

10X Genomics, Vanguard, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing